A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

4,580

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 18, 2027

Study Completion Date

October 18, 2027

Conditions

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis

Interventions

DRUG

MK-8527

Oral tablet

DRUG

Emtricitabine/tenofovir disoproxil (FTC/TDF)

Oral tablet

DRUG

Placebo matched to MK-8527

Placebo oral tablet matched to MK-8527

DRUG

Placebo matched to FTC/TDF

Placebo oral tablet matched to FTC/TDF

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY